← Leaderboards
Sandeep Patil
Praxis Bioresearch, Llc
$3,010,314
Attributed
$4,464,010
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2018–22$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,464,010 · 2
By mechanism
R44$4,464,010 · 2
Top collaborators
- William Zeigler Potter4 shared
Most similar at Praxis Bioresearch, Llc
Same institution · by research overlap
- William Zeigler Potter$1,453,697
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposS DiseaseAbsorptionWaterDesignIntravenous AdministrationIn VivoPropertySmall IntestinesStructurePancreatic DuctLipaseNovel TherapeuticsPancreasSafetyDosePharmaceutical PreparationsProdrugsIn VitroOralItalyMeetingsInvestigational DrugsHuman Study
Grant awards (8)
Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD$957,571
R44 · FY2022 · AG · contact PI
Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD$50,000
R44 · FY2022 · AG · contact PI
Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD$1,451,070
R44 · FY2021 · AG · contact PI
Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study$535,295
R44 · FY2020 · MH · contact PI
Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD$448,752
R44 · FY2020 · AG · contact PI
Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study$662,269
R44 · FY2019 · MH · contact PI
Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study$58,914
R44 · FY2019 · MH · contact PI
Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study$300,139
R44 · FY2018 · MH · contact PI